Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. I-Mab
  6. News
  7. Summary
    IMAB   US44975P1030

I-MAB

(IMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

I Mab : Piper Sandler Adjusts I-Mab PT to $90 From $75, Maintains Overweight Rating

06/07/2021 | 11:22am EDT


ę MT Newswires 2021
All news about I-MAB
10/15I MAB : Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (T..
PU
10/13I MAB : Completes Patient Enrollment in Phase 3 Study of Multiple Myeloma Therapy
MT
10/13I-MAB : Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (T..
PR
10/13I-Mab Advances Late-Stage Development of Its Differentiated CD38 Antibody Felzartamab i..
CI
10/05I-MAB : and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at th..
PR
10/05I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at t..
CI
10/04I MAB : Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzopa..
PU
10/01I-MAB : Announces Upcoming Participation at October Conferences
PR
09/30I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzop..
CI
09/29I MAB : Exploring Partnership, Stake Sale to Major Drugmakers
MT
More news
Analyst Recommendations on I-MAB
More recommendations
Financials (USD)
Sales 2021 75,7 M - -
Net income 2021 -211 M - -
Net cash 2021 689 M - -
P/E ratio 2021 -33,4x
Yield 2021 -
Capitalization 5 066 M 5 066 M -
EV / Sales 2021 57,9x
EV / Sales 2022 22,8x
Nbr of Employees 228
Free-Float 98,7%
Chart I-MAB
Duration : Period :
I-Mab Technical Analysis Chart | IMAB | US44975P1030 | MarketScreener
Technical analysis trends I-MAB
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 65,83 $
Average target price 95,07 $
Spread / Average Target 44,4%
EPS Revisions
Managers and Directors
Hua Qiong Shen Chief Executive Officer & Director
Zheru Zhang President & Director
Jielun Zhu Chief Financial Officer & Director
Jing Wu Zang Chairman
Lili Qian Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
I-MAB39.62%5 066
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.13.20%232 621
ELI LILLY AND COMPANY40.89%215 657